LONDON, Oct. 8, 2026 /PRNewswire/ -- The "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market – Growth, Share, Opportunities & Competitive Analysis, 2026–2032" report has been added to the Credence ...

The 2026 American Diabetes Association Standards of Care in Diabetes drew a line through DPP-4 inhibitors. The guideline groups the class with sulfonylureas and meglitinides as therapies whose use ...

Patients with type 2 diabetes who received dipeptidyl peptidase-4 inhibitors are at greater risk of developing pemphigus vulgaris, with the greatest risk observed among those who received linagliptin.

GLP－1受容体作動薬は、2型糖尿病や肥満症の治療薬として急速に普及している。近年の市販後調査では、同薬と脱毛との関連が指摘されているが、大規模な比較研究は十分行われてい ...

2型糖尿病の治療薬として、日本で非常に多く処方されている「DPP-4阻害薬」。 「名前は聞いたことがあるけれど、どんな仕組みで効くの？」「他の糖尿病薬と何が違うの？」という疑問を ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists for diabetes increased the risk for psoriasis and psoriatic arthritis vs. dipeptidyl ...

Among patients with type 2 diabetes, the incidence of osteoarthritis and total knee or hip replacement was lower among DPP-4 inhibitor users vs nonusers. The use of dipeptidyl peptidase-4 (DPP-4) ...

The effects of the COVID-19 pandemic on cancer incidence and cancer-specific mortality. Hazard ratios (95% CI) for incident cancer, Marketscan databases, 2016-2022.

Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Glucagon-like peptide-1 ...

岐阜大学らは、肥満マウスを用いて、DPP-4阻害薬の「血糖値の改善効果」「体重増加の抑制効果」に対し、GIPがどのように関与しているか詳細に検討し、その結果を報告した。DPP-4阻害薬が ...

Compared with DPP-4 inhibitor therapy, sustained GLP-1 receptor agonist (GLP-1 RA) therapy was associated with greater short‑ and long‑term improvements in A1c levels and a modest reduction in the ...

In patients with type 2 diabetes (T2D), the risk of hospitalization for heart failure (HHF) was significantly lower with GLP-1RAs than DPP-4 inhibitors while it was similar compared with SGLT-2 ...